Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: a prospective study of a diabetic population.
Diabetes mellitus
High mobility group box-1 (HMGB-1)
Inflammation
Lower-extremity endovascular revascularization (LER)
Peripheral artery disease (PAD)
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
16 10 2022
16 10 2022
Historique:
received:
24
08
2022
accepted:
01
10
2022
entrez:
16
10
2022
pubmed:
17
10
2022
medline:
19
10
2022
Statut:
epublish
Résumé
Peripheral arterial disease (PAD) is one of the most disabling cardiovascular complications of type 2 diabetes mellitus and is indeed associated with a high risk of cardiovascular and limb adverse events. High mobility group box-1 (HMGB-1) is a nuclear protein involved in the inflammatory response that acts as a pro-inflammatory cytokine when released into the extracellular space. HMBG-1 is associated with PAD in diabetic patients. The aim of this study was to evaluate the association between serum HMGB-1 levels and major adverse cardiovascular events (MACE) and major adverse limb events (MALE) after lower-extremity endovascular revascularization (LER) in a group of diabetic patients with chronic limb-threatening ischemia (CLTI). We conducted a prospective observational study of 201 diabetic patients with PAD and CLTI requiring LER. Baseline serum HMGB-1 levels were determined before endovascular procedure. Data on cardiovascular and limb outcomes were collected in a 12-month follow-up. During the follow-up period, 81 cases of MACE and 93 cases of MALE occurred. Patients who subsequently developed MACE and MALE had higher serum HMGB-1 levels. Specifically, 7.5 ng/mL vs 4.9 ng/mL (p < 0.01) for MACE and 7.2 ng/mL vs 4.8 ng/mL (p < 0.01) for MALE. After adjusting for traditional cardiovascular risk factors, the association between serum HMGB-1 levels and cardiovascular outcomes remained significant in multivariable analysis. In our receiver operating characteristic (ROC) curve analysis, serum HMGB-1 levels were a good predictor of MACE incidence (area under the curve [AUC] = 0.78) and MALE incidence (AUC = 0.75). This study demonstrates that serum HMGB-1 levels are associated with the incidence of MACE and MALE after LER in diabetic populations with PAD and CLTI.
Sections du résumé
BACKGROUND
Peripheral arterial disease (PAD) is one of the most disabling cardiovascular complications of type 2 diabetes mellitus and is indeed associated with a high risk of cardiovascular and limb adverse events. High mobility group box-1 (HMGB-1) is a nuclear protein involved in the inflammatory response that acts as a pro-inflammatory cytokine when released into the extracellular space. HMBG-1 is associated with PAD in diabetic patients. The aim of this study was to evaluate the association between serum HMGB-1 levels and major adverse cardiovascular events (MACE) and major adverse limb events (MALE) after lower-extremity endovascular revascularization (LER) in a group of diabetic patients with chronic limb-threatening ischemia (CLTI).
METHODS
We conducted a prospective observational study of 201 diabetic patients with PAD and CLTI requiring LER. Baseline serum HMGB-1 levels were determined before endovascular procedure. Data on cardiovascular and limb outcomes were collected in a 12-month follow-up.
RESULTS
During the follow-up period, 81 cases of MACE and 93 cases of MALE occurred. Patients who subsequently developed MACE and MALE had higher serum HMGB-1 levels. Specifically, 7.5 ng/mL vs 4.9 ng/mL (p < 0.01) for MACE and 7.2 ng/mL vs 4.8 ng/mL (p < 0.01) for MALE. After adjusting for traditional cardiovascular risk factors, the association between serum HMGB-1 levels and cardiovascular outcomes remained significant in multivariable analysis. In our receiver operating characteristic (ROC) curve analysis, serum HMGB-1 levels were a good predictor of MACE incidence (area under the curve [AUC] = 0.78) and MALE incidence (AUC = 0.75).
CONCLUSIONS
This study demonstrates that serum HMGB-1 levels are associated with the incidence of MACE and MALE after LER in diabetic populations with PAD and CLTI.
Identifiants
pubmed: 36244983
doi: 10.1186/s12933-022-01650-1
pii: 10.1186/s12933-022-01650-1
pmc: PMC9571458
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
214Informations de copyright
© 2022. The Author(s).
Références
J Am Coll Cardiol. 2018 Aug 28;72(9):999-1011
pubmed: 30139446
Ann Vasc Surg. 2013 May;27(4):459-66
pubmed: 23403331
Shock. 2006 Jun;25(6):571-4
pubmed: 16721263
Cardiovasc Diabetol. 2020 Sep 25;19(1):147
pubmed: 32977814
PLoS One. 2014 Dec 09;9(12):e114429
pubmed: 25490770
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Diabetes Res Clin Pract. 2010 Nov;90(2):167-72
pubmed: 20822820
J Am Coll Cardiol. 2018 Oct 2;72(14):1563-1572
pubmed: 30261955
Histol Histopathol. 2014 Feb;29(2):235-42
pubmed: 23929500
J Immunol. 2004 Jul 1;173(1):307-13
pubmed: 15210788
Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
Semin Vasc Surg. 2014 Mar;27(1):16-22
pubmed: 25812755
Diabetes Care. 2019 Oct;42(10):1939-1945
pubmed: 31371431
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
Atherosclerosis. 2009 Aug;205(2):544-8
pubmed: 19150066
Cardiovasc Diabetol. 2017 Aug 8;16(1):99
pubmed: 28789654
J Vasc Surg. 2014 Jan;59(1):220-34.e1-2
pubmed: 24126108
J Vasc Surg. 2021 Dec;74(6):2014-2022.e4
pubmed: 34182034
Circulation. 2016 Mar 8;133(10):997-1005
pubmed: 26826179
PLoS One. 2012;7(12):e52081
pubmed: 23284878
Mediators Inflamm. 2016;2016:3896147
pubmed: 27847406
Int J Mol Sci. 2021 Feb 18;22(4):
pubmed: 33670461
J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S395-404
pubmed: 14514855
Radiology. 2003 May;227(2):419-25
pubmed: 12649419
J Intern Med. 2007 Jul;262(1):124-30
pubmed: 17598820
Circulation. 2018 Jan 23;137(4):338-350
pubmed: 29133605
Cardiovasc Pathol. 2007 May-Jun;16(3):136-43
pubmed: 17502242
Cardiovasc Diabetol. 2016 Sep 02;15(1):129
pubmed: 27590190
Curr Vasc Pharmacol. 2018;16(6):547-554
pubmed: 28762307
Int J Mol Sci. 2019 Dec 11;20(24):
pubmed: 31835864
Circulation. 2008 Jun 24;117(25):3216-26
pubmed: 18574060
PLoS One. 2015 Aug 28;10(8):e0136564
pubmed: 26317615
Circulation. 2020 Dec 8;142(23):2219-2230
pubmed: 33138628
Asian Cardiovasc Thorac Ann. 2019 May;27(4):251-255
pubmed: 30818961
Nat Rev Immunol. 2005 Apr;5(4):331-42
pubmed: 15803152
J Clin Invest. 2015 Dec;125(12):4638-54
pubmed: 26551681
Cardiovasc Diabetol. 2020 Oct 7;19(1):170
pubmed: 33028322
Eur J Vasc Endovasc Surg. 2019 Jul;58(1S):S1-S109.e33
pubmed: 31182334
J Intern Med. 2004 Mar;255(3):332-43
pubmed: 14871457
FASEB J. 2006 Dec;20(14):2565-6
pubmed: 17060403
J Vasc Surg. 1997 Sep;26(3):517-38
pubmed: 9308598
Diabetes Care. 2002 May;25(5):894-9
pubmed: 11978687
Diabetes Care. 2014;37(5):1346-52
pubmed: 24595631
JACC Cardiovasc Interv. 2011 Mar;4(3):281-6
pubmed: 21435605
Atherosclerosis. 2012 Apr;221(2):490-5
pubmed: 22369934
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Clin Chim Acta. 2009 Aug;406(1-2):139-42
pubmed: 19545550
EMBO Rep. 2004 Aug;5(8):825-30
pubmed: 15272298
Thromb Haemost. 2015 Nov;114(5):994-1003
pubmed: 26202300
Diabetes Care. 2020 Jul;43(7):1557-1592
pubmed: 33534729
Cardiovasc Diabetol. 2021 May 27;20(1):114
pubmed: 34044825
Curr Vasc Pharmacol. 2011 Nov;9(6):677-81
pubmed: 21692740
J Am Heart Assoc. 2018 Oct 2;7(19):e008596
pubmed: 30371306
Int J Cardiol. 2017 Dec 15;249:349-356
pubmed: 28967436
J Vasc Surg. 1986 Jul;4(1):80-94
pubmed: 3723692
J Am Coll Cardiol. 2020 May 5;75(17):2122-2135
pubmed: 32354380
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
Cardiovasc Res. 2009 Feb 15;81(3):565-73
pubmed: 18984601
J Am Coll Cardiol. 2013 Jan 29;61(4):404-410
pubmed: 23265346
J Am Coll Cardiol. 2018 Dec 25;72(25):3274-3284
pubmed: 30573030
Int J Mol Sci. 2020 Mar 06;21(5):
pubmed: 32155866
J Vasc Surg. 2015 Feb;61(2):374-81
pubmed: 25441669
Thromb Haemost. 2009 Aug;102(2):352-9
pubmed: 19652887
Diabetes. 2010 Jun;59(6):1496-505
pubmed: 20200317